Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has been assigned an average recommendation of “Buy” from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $37.70.

Several equities research analysts recently issued reports on the stock. Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, September 3rd. B. Riley lifted their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, December 1st. Wells Fargo & Company increased their price objective on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Finally, Oppenheimer lifted their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $26.51 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The stock’s fifty day moving average is $25.57 and its two-hundred day moving average is $19.69. The firm has a market capitalization of $3.56 billion, a P/E ratio of -14.49 and a beta of 1.55. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $22.41, for a total value of $134,460.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at approximately $2,361,700.26. The trade was a 5.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the transaction, the chief technology officer directly owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. This trade represents a 24.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 113,172 shares of company stock valued at $2,820,441. 7.09% of the stock is currently owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in CNTA. Avoro Capital Advisors LLC grew its position in Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 35.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company’s stock valued at $99,999,000 after purchasing an additional 1,834,973 shares during the period. Federated Hermes Inc. purchased a new position in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $42,429,000. Balyasny Asset Management L.P. acquired a new position in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $16,052,000. Finally, Commodore Capital LP increased its stake in Centessa Pharmaceuticals by 39.3% during the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after buying an additional 930,711 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.